Two new studies that compared antipsychotics seek to fill that gap. The first, which Hamina led, measured the efficacy of ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat ...

Teva already presented in June 2024 data informing clinical strategies for switching patients to UZEDY from a once-monthly intramuscular injection of Invega Sustenna ® (paliperidone palmitate) ...

INVEGA HAFYERA contains the active ingredient paliperidone palmitate. INVEGA HAFYERA is used to treat schizophrenia in adults (18 years of age and older). For more information, see Section 1.

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in ...